Media Articles Related to Requip XL (Ropinirole)
Patients with Parkinson's Disease often suffer from undiagnosed depression
Source: Depression News From Medical News Today [2014.08.19]
Depression is known to be a common symptom of Parkinson's disease, but remains untreated for many patients, according to a new study by Northwestern Medicine investigators in collaboration with the...
Naltrexone may be effective in diminishing impulse control disorders in Parkinson's disease
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2014.08.02]
Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as...
Source: MedicineNet amantadine Specialty [2013.12.04]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/4/2013 12:00:00 AM
Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet levodopa-carbidopa Specialty [2011.08.31]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 8/31/2011 2:27:29 PM
Impulse control increased by dopamine replacement in early Parkinson's
Source: Anxiety / Stress News From Medical News Today [2014.08.19]
New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson's disease (PD) patients compared to the general...
Published Studies Related to Requip XL (Ropinirole)
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. [2011.06]
BACKGROUND: PREPARED was a randomized, parallel-group, double-blind, multicenter study to evaluate the efficacy of adjunctive ropinirole prolonged release (PR) versus immediate release (IR) in patients with advanced Parkinson's disease (PD)... CONCLUSIONS: Adjunctive PR provided a significantly greater improvement in symptom control in terms of the odds of achieving >/= 20% maintained reduction in time spent "off" compared with IR. Interpretation may be confounded by the higher doses of PR versus IR that were achieved, in combination with lower doses of L-dopa by the study end. Despite dosing differences, the PR titration regimen was generally well tolerated, with an AE profile similar to that of IR. Copyright (c) 2011 Movement Disorder Society.
Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. [2011.06]
Comorbid depressive symptoms in restless legs syndrome (RLS) remain a treatment challenge, as some antidepressants aggravate RLS symptoms...
Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. [2011.04]
BACKGROUND: Pramipexole and ropinirole have become the first-line treatment for restless legs syndrome. The aim of this study was to perform the first direct comparison between these two molecules in restless legs syndrome... No significant side effects, except for mild morning nausea (2 patients treated with ropinirole, 3 with pramipexole, and 1 with placebo), were reported.
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. [2010.05.15]
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa...
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. [2010.05.15]
Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104)...
Clinical Trials Related to Requip XL (Ropinirole)
Study to Observe the Effect of Requip PDŽ Once-daily (QD) Versus Twice-daily (BID) [Recruiting]
1. In order to observe the benefit, side effects, and patient preference of Requip PD when
used in QD or BID dosing
2. In order to estimate the conversion rate of dopamine agonists into Requip PD
SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole [Recruiting]
The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole
for patients switched from pramipexole to ropinirole in patients with moderate to severe
primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with
Restless Legs Syndrome can maintain stable efficacy and tolerability if correctly switched
from one dopamine agonist to an equipotent dose of another.
Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease [Recruiting]
The purpose of this research study is to see if subjects with Parkinson's disease who are
experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary
excessive movements) would benefit from a higher dose of Requip as compared to the maximum
FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip
as used in this study is investigational, which means it has not been approved by the US
Food and Drug Administration (FDA) at this dose level.
Ropinirole in the Treatment of Bipolar Depression [Recruiting]
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease [Recruiting]
This study is a fixed dose, dose response study to characterize the dose response for
ropinirole PR in early stage PD patients (Hoehn & Yahr stages I-III). After screening and
baseline assessments, subjects will be randomized to one of six final target treatment
groups (placebo, 2, 4, 8, 12 or 24mg/day ropinirole PR). The study will consist of a
screening period, an up-titration period, a maintenance period, a down titration period and
a follow up period. This study utilizes change from baseline in the UPDRS motor score as the
primary endpoint, in line with that used in the ropinirole PR monotherapy pivotal study
(SK&F101468/168). Clinical review of the primary and secondary endpoints will be performed
in order to establish the lowest maximally effective therapeutic dose.
Reports of Suspected Requip XL (Ropinirole) Side Effects
Medication Residue (8),
Drug Ineffective (6),
OFF Label USE (6),
Drug Administration Error (5),
Hallucination, Visual (5),
Malaise (4), more >>